KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Income from Continuing Operations (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Income from Continuing Operations for 17 consecutive years, with 1086000000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 1328.95% to 1086000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 7056000000.0, a 178.99% increase, with the full-year FY2025 number at 7056000000.0, up 178.99% from a year prior.
  • Income from Continuing Operations was 1086000000.0 for Q4 2025 at Bristol Myers Squibb, down from 2195000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2462000000.0 in Q1 2025 to a low of 11908000000.0 in Q1 2024.
  • A 5-year average of 976100000.0 and a median of 1646000000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: surged 1426.25% in 2021, then plummeted 625.28% in 2024.
  • Bristol Myers Squibb's Income from Continuing Operations stood at 2372000000.0 in 2021, then decreased by 14.63% to 2025000000.0 in 2022, then decreased by 12.99% to 1762000000.0 in 2023, then plummeted by 95.69% to 76000000.0 in 2024, then skyrocketed by 1328.95% to 1086000000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMY's Income from Continuing Operations are 1086000000.0 (Q4 2025), 2195000000.0 (Q3 2025), and 1313000000.0 (Q2 2025).